Navigation Links
Oregon Health Care Quality Corporation Receives Important Designation from U.S. Department of Health and Human Services
Date:3/19/2008

Secretary Leavitt to present the Chartered Value Exchange designation and

meet with community leaders during March 20 visit to Portland

PORTLAND, Ore., March 19 /PRNewswire/ -- In recognition of the organization's efforts to improve care and physician practices in Oregon, The Oregon Health Care Quality Corporation (Quality Corp) is receiving the Chartered Value Exchange designation from the U.S. Department of Health and Human Services.

HHS is recognizing 14 community-based organizations around the country as the first Chartered Value Exchanges, and Secretary Leavitt will personally recognize Quality Corp during his Portland visit. The organization is being recognized for taking clear actions to convene community purchasers, health plans, providers and consumers to advance value-driven health care.

Specifically, Quality Corp is focused on the following efforts:

-- Giving people information that helps them be better partners with their

doctors in managing their own health.

-- Learning how doctors and hospitals how they can make improvements in

caring for patients.

-- Helping purchasers get the information they need in order to buy high

value health care.

-- Encouraging systems to get patients' information to where it is needed

for good care.

"Quality health care happens when doctors, nurses and patients are all on the same team with the same expectations," said Nancy Clarke, Executive Director of the Oregon Health Care Quality Corporation. "Information about cost and quality, provided in the right way, can encourage a much stronger partnership between patients and their provider teams, leading to better health."

The Quality Corp, in addition to other groups receiving the designation, will receive access to Medicare provider performance information for their communities, which can be combined with similarly calculated private-sector results to produce
'/>"/>

SOURCE Oregon Health Care Quality Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Phlo Affiliate Reports Expanded Coverage to Oregon Border
2. Assured Pharmacy Consolidates Portland, Oregon Pharmacy
3. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
4. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
5. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
10. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
11. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rcv4lq/gene_therapy ... Therapy Market, 2015 - 2025" report to their ... report provides an extensive study on the marketed and ... carried out in this field for over a decade ... in Asian markets; one approved in the EU). There ...
(Date:3/3/2015)... California (PRWEB) March 03, 2015 Crown ... service company, has launched a new Life Science division ... for preclinical research. , The first products released ... isotype controls, and soon to be released in vivo ... will continue to expand their life science portfolio with ...
(Date:3/3/2015)... March 3, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... scientific journal, Expert Opinion on Biological Therapy , ... Zhenggang Zhang , at the Henry Ford Hospital ... Thymosin beta 4 (TB4) has the capacity to promote ... or more post-injury, leading to neurological recovery in each ...
(Date:3/3/2015)... Liberty Corner, New Jersey (PRWEB) March 03, 2015 ... in NJ, has announced today that it has ... DE. Terms of the transaction were not ... engineering consulting services to the energy sector including ... gas, alternative energy, and fossil and nuclear power ...
Breaking Biology Technology:Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 2Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 3Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 4Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 5Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 6Global Gene Therapy Market Report 2015-2025 - Extensive Study on the Marketed and Pipeline Gene Therapies 7Crown Bioscience Launches Life Science Product Catalog 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
... NATICK, Mass., Nov. 9, 2010 Boston Scientific Corporation ... implantation of its Vercise™ Deep Brain Stimulation (DBS) System ... a multi-center, prospective trial designed to examine the improvement ... with the Vercise DBS System for the treatment of ...
... Life Sciences Holdings, Inc. (OTC Bulletin Board: ... discovery, development and commercialization of novel drugs in the ... announced that it has submitted a full proposal to ... under BAA-NIAID-DMID-NIHAI2010097 Development Of Therapeutics For Biodefense . ...
... Professor Andre Geim, who along with his colleague Professor ... the world,s thinnest material, has now modified it ... to Teflon. Fluorographene is fully-fluorinated graphene and is ... including chemical inertness and thermal stability. The ...
Cached Biology Technology:Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease 2Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease 3Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease 4Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 2Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 3Advanced Life Sciences Submits Full Proposal to NIAID for Development of Intravenous Formulation of Restanza as a Biodefense Countermeasure 4Graphene gets a Teflon makeover 2Graphene gets a Teflon makeover 3
(Date:2/13/2015)... Feb. 13, 2015 ACT Genomics Co., ... aims to transform cancer genomic information into precision ... company has raised US$ 8 million in the its ... Taipei, Taiwan , ACT Genomics ... With the aim to implement next generation sequencing ...
(Date:2/9/2015)... 9, 2015  Lintec of America recently announced an ... nanotube (CNT) macrostructures, including sheets, yarns and ribbons, developed ... Leveraging the vast industrial resources of the global ... , Lintec of America is forming the Nano-Science and ... , focusing on scaling up the manufacturing and commercialization ...
(Date:2/5/2015)... , Jan. 27, 2015   ... of globally deployed, innovative test solutions for ... the delivery of its TS-323 GENASYS ... Systems Company (LMSSC). GENASYS is a high-performance ... of mission-critical applications that require performance functional ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
... to a report issued last week by UNAIDS, access ... worldwide. But Dr. Groesbeck Parham, gynecologic oncologist and ... Center for Infectious Disease Research in Zambia (CIDRZ) warns ... dying of cervical cancer unless they have access to ...
... at The University of Manchester have developed a new x-ray ... and human cancers more effectively. Professor Robert Cernik and ... colour 3D X-ray system that allows material at each point ... work is reported in the latest issue of The Journal ...
... for commercial genetic testing is on the rise and ... (MGH) physician. In the December issue of Obstetrics ... testing is poorly regulated and may present potential pitfalls ... that are being offered have no proven clinical validity ...
Cached Biology News:Women with AIDS face cervical cancer threat 2New X-ray technique targets terrorists and tumors 2Direct-to-consumer advertising for genetic tests concerns physicians and may mislead patients 2
Endomorphin-2. Cross reactivity: Endomorphin-1 3%, Met-enkephalin <0.03%, Leu-enkephalin <0.01% and beta-Endorphin <0.01%....
... cloning of BAC (100+kb), fosmid (40kb), and ... stability than any othe BAC vector. On ... yields and easy recombinant DNA purification. Available ... (pSMART VC) vectors for the highest insert ...
6-carboxy-2',4,4',5',7,7'-hexachlorofluorescein, succinimidyl ester (6-HEX, SE) *single isomer*...
Fibulin-2 (D-15)...
Biology Products: